ExeGi Pharma is at the forefront of developing innovative biotherapeutics and probiotics, leveraging advancements in microbiome science to address various unmet medical needs. The company focuses on creating live biotherapeutic products (LBPs) that are clinically supported and formulated to provide effective treatments. One of their key products, EXE-346, is a live biotherapeutic biologic drug designed to manage excessive stool frequency in patients who have undergone ileal pouch-anal anastomosis (IPAA). This product is notable for its high potency and is manufactured to biologic-grade cGMP standards, ensuring quality and efficacy.

The company has recently received FDA clearance for the Investigational New Drug (IND) application for EXE-346, allowing them to initiate clinical trials aimed at evaluating the safety and efficacy of this treatment. This development is particularly significant as there are currently no approved therapies for managing excessive stool frequency in J-Pouch patients, highlighting the potential impact of ExeGi's research on patient care. By focusing on live biotherapeutics, ExeGi Pharma aims to revolutionize treatment approaches for gastrointestinal conditions, ultimately improving the quality of life for patients and their pets.

United States

ExeGi Pharma is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. Our team leverages the field of microbiome science to deliver novel, clinically supported, live biotherapeutic and probiotic treatments for a variety of unmet medical needs for both humans and veterinary applications. Makers of Visbiome and Visbiome Vet high potency probiotics.

ExeGi Pharma

Company Details